Why the study?
How do changes in novel metrics of HDL over the menopausal transition impact cardiovascular disease risk later in life?
How do changes in novel metrics of HDL over the menopausal transition impact cardiovascular disease risk later in life?
Future longitudinal studies are needed to evaluate novel HDL metrics to better understand the association between menopause, HDL, and CVD risk.
Answers are grounded in this paper and cite their sources.
Current evidence does not support using novel HDL metrics in perimenopausal care; leaves open their link to later CVD.
The impact of changes in novel metrics of HDL over the menopausal transition on cardiovascular disease (CVD) risk later in life is not clear in women. Much of our understanding of how the menopausal transition may impact HDL metrics comes from cross-sectional studies. Future longitudinal studies are needed to evaluate other metrics of HDL shown to better reflect the cardio-protective capacities of HDL, so that the complex association of menopause, HDL and CVD risk could be characterized.
No takes yet. Share an insight, caveat, or question.
Samar R. El Khoudary (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: